Radioimmunotherapy for treatment of acute leukemia

Seminars in Nuclear Medicine

Volumn 46, Issue 2, 2016, Pages 135-146

  Bodet Milin, Caroline ^a,b   Kraeber Bodéré, Françoise ^a,b,c   Eugène, Thomas ^b   Guérard, François ^a   Gaschet, Joëlle ^a   Bailly, Clément ^b   Mougin, Marie ^a,b   Bourgeois, Mickaël ^a,b   Faivre Chauvet, Alain ^a,b   Chérel, Michel ^a,c   Chevallier, Patrice ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UMR INSERM U892 CNRS 6299   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD22 ANTIBODY; CD33 ANTIBODY; CD45 ANTIBODY; CD66 ANTIBODY; UNCLASSIFIED DRUG; LEUKOCYTE ANTIGEN;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; MULTIMODALITY CANCER THERAPY; RADIOIMMUNOTHERAPY; TREATMENT INDICATION; ACUTE DISEASE; ANIMAL; HUMAN; IMMUNOLOGY; LEUKEMIA; PROCEDURES;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD; HUMANS; LEUKEMIA; RADIOIMMUNOTHERAPY;

EID: 84958762694     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2015.10.007     Document Type: Review

References (67)

1. J. Barbet, M. Bardiès, M. Bourgeois, and et al. Radiolabeled antibodies for cancer imaging and therapy Methods Mol Biol 907 2012 681 697 10.1007/978-1-61779-974-7-38
2. J.-P. Pouget, I. Navarro-Teulon, M. Bardiès, and et al. Clinical radioimmunotherapy - The role of radiobiology Nat Rev Clin Oncol 8 12 2011 720 734 10.1038/nrclinonc.2011.160
3. J.-B. Gorin, J. Ménager, S. Gouard, and et al. Antitumor immunity induced after α irradiation Neoplasia 16 4 2014 319 328 10.1016/j.neo.2014.04.002
4. S.M. Larson, J.A. Carrasquillo, N-KV Cheung, and et al. Radioimmunotherapy of human tumours Nat Rev Cancer 15 6 2015 347 360 10.1038/nrc3925
5. F. Kraeber-Bodéré, C. Bodet-Milin, C. Rousseau, and et al. Radioimmunoconjugates for the treatment of cancer Semin Oncol 41 5 2014 613 622 10.1053/j.seminoncol.2014.07.004
6. C. Bodet-Milin, L. Ferrer, A. Pallardy, and et al. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma Front Oncol 3 2013 177 10.3389/fonc.2013.00177
7. T.E. Witzig, A. Molina, L.I. Gordon, and et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan Cancer 109 9 2007 1804 1810 10.1002/cncr.22617
8. F. Morschhauser, J. Radford, A. Van Hoof, and et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 26 32 2008 5156 5164 10.1200/JCO.2008.17.2015
9. 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: An international phase II study in patients requiring treatment according to GELF/BNLI criteria J Clin Oncol 32 3 2014 212 218 10.1200/JCO.2013.50.3110
10. R.I. Fisher, M.S. Kaminski, R.L. Wahl, and et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas J Clin Oncol 23 30 2005 7565 7573 10.1200/JCO.2004.00.9217
11. F. Morschhauser, F. Kraeber-Bodéré, W.A. Wegener, and et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: Results of a multicenter, phase I/II study in non-Hodgkin's lymphoma J Clin Oncol 28 23 2010 3709 3716 10.1200/JCO.2009.27.7863
12. T.M. Illidge Radioimmunotherapy of lymphoma: A treatment approach ahead of its time or past its sell-by date? J Clin Oncol 28 18 2010 2944 2946 10.1200/JCO.2009.26.8748
13. C. Rousseau, L. Ferrer, S. Supiot, and et al. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients Tumour Biol 33 3 2012 679 688 10.1007/s13277-012-0362-y
14. M. Chérel, S. Gouard, J. Gaschet, and et al. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma J Nucl Med 54 9 2013 1597 1604 10.2967/jnumed.112.111997
15. S. Gouard, A. Pallardy, J. Gaschet, and et al. Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy Nucl Med Biol 41 2014 e30 e35 10.1016/j.nucmedbio.2014.02.008 (suppl)
16. J.G. Jurcic, S.M. Larson, G. Sgouros, and et al. Targeted alpha particle immunotherapy for myeloid leukemia Blood 100 4 2002 1233 1239
17. J. Barbet, M. Chérel, and J.-F. Chatal Alpha particles more promising than toxins? Eur J Nucl Med Mol Imaging 37 5 2010 849 850 10.1007/s00259-010-1421-5
18. J.-F. Chatal, F. Davodeau, M. Cherel, and et al. Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors J Cancer Res Ther 5 2009 S36 S40 10.4103/0973-1482.55139 (suppl 1)
19. G. Sgouros, J.C. Roeske, M.R. McDevitt, and et al. MIRD Pamphlet No. 22 (abridged): Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy J Nucl Med 51 2 2010 311 328 10.2967/jnumed.108.058651
20. H. Döhner, E.H. Estey, S. Amadori, and et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 3 2010 453 474 10.1182/blood-2009-07-235358
21. C.-H. Pui, L.L. Robison, and A.T. Look Acute lymphoblastic leukaemia Lancet 371 9617 2008 1030 1043 10.1016/S0140-6736(08)60457-2
22. M.C. Béné, T. Nebe, P. Bettelheim, and et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: A consensus proposal of the European LeukemiaNet Work Package 10 Leukemia 25 4 2011 567 574 10.1038/leu.2010.312
23. K. Beldjord, S. Chevret, V. Asnafi, and et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia Blood 123 24 2014 3739 3749 10.1182/blood-2014-01-547695
24. P. Chevallier, N. Robillard, G. Houille, and et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: A monocentric study of 44 cases Leukemia 23 4 2009 806 807 10.1038/leu.2008.303
25. P. Chevallier, F. Huguet, E. Raffoux, and et al. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: A phase II study Haematologica 100 4 2015 e128 e131 10.3324/haematol.2014.120220
26. D.A. Scheinberg, D. Lovett, C.R. Divgi, and et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide J Clin Oncol 9 3 1991 478 490
27. M.A. Schwartz, D.R. Lovett, A. Redner, and et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias J Clin Oncol 11 2 1993 294 303
28. J.G. Jurcic, P.C. Caron, T.K. Nikula, and et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias Cancer Res 55 23 1995 5908s 5910s (suppl)
29. M.R. McDevitt, R.D. Finn, D. Ma, and et al. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use J Nucl Med 40 10 1999 1722 1727
30. T.K. Nikula, M.R. McDevitt, R.D. Finn, and et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry J Nucl Med 40 1 1999 166 176
31. G. Sgouros, A.M. Ballangrud, J.G. Jurcic, and et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia J Nucl Med 40 11 1999 1935 1946
32. T.L. Rosenblat, M.R. McDevitt, D.A. Mulford, and et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia Clin Cancer Res 16 21 2010 5303 5311 10.1158/1078-0432.CCR-10-0382
33. M.R. McDevitt, D. Ma, L.T. Lai, and et al. Tumor therapy with targeted atomic nanogenerators Science 294 5546 2001 1537 1540 10.1126/science.1064126
34. J.G. Jurcic, T.L. Rosenblat, M.R. McDevitt, and et al. Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac)-lintuzumab (Anti-CD33; HuM195) in acute myeloid leukemia (AML) ASH Annu Meet Abstr 118 21 2011 768
35. J.G. Jurcic, and T.L. Rosenblat Targeted alpha-particle immunotherapy for acute myeloid leukemia Am Soc Clin Oncol Educ Book 2014 e126 e131 10.14694/EdBook-AM.2014.34.e126
36. M.B. Omary, I.S. Trowbridge, and H.A. Battifora Human homologue of murine T200 glycoprotein J Exp Med 152 4 1980 842 852
37. O.W. Press, A.G. Farr, K.I. Borroz, and et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies Cancer Res 49 17 1989 4906 4912
38. R.H. van der Jagt, C.C. Badger, F.R. Appelbaum, and et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model Cancer Res 52 1 1992 89 94
39. D.C. Matthews, F.R. Appelbaum, J.F. Eary, and et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome Blood 94 4 1999 1237 1247
40. J.M. Pagel, F.R. Appelbaum, J.F. Eary, and et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission Blood 107 5 2006 2184 2191 10.1182/blood-2005-06-2317
41. J.M. Pagel, T.A. Gooley, J. Rajendran, and et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome Blood 114 27 2009 5444 5453 10.1182/blood-2009-03-213298
42. D.C. Matthews, F.R. Appelbaum, J.F. Eary, and et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation Blood 85 4 1995 1122 1131
43. R. Mawad, T.A. Gooley, J.G. Rajendran, and et al. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome Biol Blood Marrow Transplant 20 9 2014 1363 1368 10.1016/j.bbmt.2014.05.014
44. J.J. Orozco, E.R. Balkin, T.A. Gooley, and et al. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model PloS One 9 12 2014 e113601 10.1371/journal.pone.0113601
45. J.J. Orozco, T. Bäck, A. Kenoyer, and et al. Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model Blood 121 18 2013 3759 3767 10.1182/blood-2012-11-467035
46. J.M. Pagel, N. Hedin, L. Drouet, and et al. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy Blood 111 4 2008 2261 2268 10.1182/blood-2007-06-097451
47. D.M. Goldenberg, R.M. Sharkey, G. Paganelli, and et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy J Clin Oncol 24 5 2006 823 834 10.1200/JCO.2005.03.8471
48. D.J. Green, J.M. Pagel, E.R. Nemecek, and et al. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates Blood 114 6 2009 1226 1235 10.1182/blood-2009-03-210344
49. J.M. Pagel, A.L. Kenoyer, T. Bäck, and et al. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: High rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model Blood 118 3 2011 703 711 10.1182/blood-2011-04-347039
50. J. Kotzerke, D. Bunjes, and D.A. Scheinberg Radioimmunoconjugates in acute leukemia treatment: The future is radiant Bone Marrow Transplant 36 12 2005 1021 1026 10.1038/sj.bmt.1705182
51. I. Buchmann, T. Kull, G. Glatting, and et al. A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy Eur J Nucl Med Mol Imaging. 30 5 2003 667 673 10.1007/s00259-002-1106-9
52. M. Ringhoffer, N. Blumstein, B. Neumaier, and et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: Results of a phase I-II study Br J Haematol 130 4 2005 604 613 10.1111/j.1365-2141.2005.05663.x
53. A.S. Schulz, G. Glatting, M. Hoenig, and et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases Blood 117 17 2011 4642 4650 10.1182/blood-2010-06-284349
54. C. Koenecke, M. Hofmann, O. Bolte, and et al. Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia Int J Hematol 87 4 2008 414 421 10.1007/s12185-008-0043-1
55. E.M. Röttinger, D. Bartkowiak, D. Bunjes, and et al. Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy Strahlenther Onkol 179 10 2003 702 707 10.1007/s00066-003-1090-4
56. T. Zenz, R.F. Schlenk, G. Glatting, and et al. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation J Nucl Med 47 2 2006 278 286
57. D. Bunjes, I. Buchmann, C. Duncker, and et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: Results of a phase I-II study Blood 98 3 2001 565 572
58. A. Lauter, A. Strumpf, U. Platzbecker, and et al. 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation Br J Haematol 148 6 2010 910 917 10.1111/j.1365-2141.2009.08025.x
59. S. Schneider, A. Strumpf, J. Schetelig, and et al. Reduced-intensity conditioning combined with (188)Rhenium radioimmunotherapy before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: The role of in vivo t cell depletion Biol Blood Marrow Transplant 2015 10.1016/j.bbmt.2015.05.012
60. P. Kletting, C. Maaß, S. Reske, and et al. Physiologically based pharmacokinetic modeling is essential in 90Y-labeled anti-CD66 radioimmunotherapy PloS One 10 5 2015 e0127934 10.1371/journal.pone.0127934
61. D. Putzer, G. Dobrozemsky, R. Haubner, and et al. 124I-anti-CD52 dosimetry before radioimmunotherapy as part of conditioning for stem cell transplantation in acute leukemia Clin Nucl Med 37 4 2012 390 392 10.1097/RLU.0b013e3182443b64
62. P. Chevallier, C. Bodet-Milin, N. Robillard, and et al. BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: Proof of principle Eur J Haematol 91 6 2013 552 556 10.1111/ejh.12183
63. P. Chevallier, T. Eugene, N. Robillard, and et al. 90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: A phase 1 dose-escalation study Lancet Haematol 2 3 2015 e108 e117 10.1016/S2352-3026(15)00020-4
64. E.A. Raetz, M.S. Cairo, M.J. Borowitz, and et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A Children's Oncology Group Pilot Study J Clin Oncol 26 22 2008 3756 3762 10.1200/JCO.2007.15.3528
65. A.S. Advani, S. McDonough, S. Coutre, and et al. SWOG S0910: A phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia Br J Haematol 165 4 2014 504 509 10.1111/bjh.12778
66. J. Carnahan, R. Stein, Z. Qu, and et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab Mol Immunol 44 6 2007 1331 1341 10.1016/j.molimm.2006.05.007
67. Kraeber-Bodere F, Pallardy A, Le Gouill S: Consolidation Anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients: A LYSA Phase II prospective trial